Company intelligence / Profile preview
TAE Life Sciences
- Ownership
- Private
- Development stage
- Preclinical
Overview
TAE Life Sciences’ investigational Alphabeam™ BNCT system and proprietary boronated drugs have shown promising preclinical results for treating aggressive and refractory cancers. The company has established strategic partnerships to advance clinical development but does not yet have commercial products on the market.
- Therapeutic areas
- Oncology
- Modalities
- Targeted radiotherapy (Boron Neutron Capture Therapy / BNCT)Small molecule boronated drugs (e.g., boronophenylalanine/BPA, Boronotyrosine/BTS)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on TAE Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAE Life Sciences.